SALT LAKE CITY--( BUSINESS WIRE )--Foldax, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted IDE approval to begin an Early Feasibility Study of the Tria surgical aortic heart valve for the treatment of aortic valve disease.
Foldax, Inc. Gains Approval to Begin US Clinical Trials of the First and Only Biopolymer Heart Valve Platform
Disclosure: This site contains some affiliate links. We might receive a small commission at no additional cost to you.